Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies against novel targets for a broad range of immunological diseases and cancer, announced today that clinical data for its lead drug candidate, ELA026, will be presented as one of five selected abstracts in a late-breaking oral session at the European Hematology Association (EHA) Congress.
Data from Phase 1b study of ELA026 in secondary hemophagocytic lymphohistiocytosis (sHLH) to be presented on Sunday, June 16, 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies against novel targets for a broad range of immunological diseases and cancer, announced today that clinical data for its lead drug candidate, ELA026, will be presented as one of five selected abstracts in a late-breaking oral session at the European Hematology Association (EHA) Congress. The conference is being held in Madrid, Spain and live-streamed on June 13-16, 2024.
The oral presentation will describe clinical data from a Phase 1b study of ELA026 for the treatment of secondary hemophagocytic lymphohistiocytosis (sHLH), a rare, life-threatening hyperinflammatory disease for which there is currently no approved treatment. ELA026 is a monoclonal antibody that targets signal regulatory protein (SIRP)-α/β1/γ, enabling precise depletion of pathologic immune cells. The abstract is published on the EHA website here.
Details of the oral presentation are as follows:
| Title: | ELA026 Targeting of SIRP(+) Immune Cells Results in a High Response Rate and Improved 2-Month Survival of Treatment-Naïve Malignancy-Associated Hemophagocytic Lymphohistiocytosis in a Phase 1 Study |
| Presenter: | Abhishek Maiti, MD, Assistant Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center |
| Session Name: | Late-Breaking Oral Session |
| Session Date & Time: | Sunday, June 16, 2024, 9:45 – 11:15 a.m. Central European Summer Time |
| Location: | Madrid Recinto Ferial Hall Picasso, and livestreamed on the EHA Congress platform |
| Abstract Code: | LB3442 |
About Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
Secondary hemophagocytic lymphohistiocytosis (sHLH) is a rare, life-threatening inflammatory disease for which there is no approved treatment. It can be triggered by cancer (malignancy-associated HLH, or mHLH), infection, autoimmune disease, or immunotherapy. sHLH is associated with a systemic inflammatory response for which patients require immediate intervention. Without treatment, patients may experience multiple organ failure and death. sHLH has a high mortality rate during the first months of diagnosis, with mHLH patients having the poorest outcomes.
About Electra Therapeutics
Electra Therapeutics is a clinical stage biotechnology company developing therapies against novel targets for a broad range of immunological diseases and cancer. The company’s lead product candidate, ELA026, is a monoclonal antibody that targets SIRP on the cell surface of myeloid cells and T lymphocytes, and precisely depletes pathological immune cells. ELA026 is in clinical development for secondary hemophagocytic lymphohistiocytosis (sHLH), a rare, life-threatening hyperinflammatory condition for which there is no approved treatment, as well as additional disease indications. For more information, please visit www.electra-therapeutics.com and follow us on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240602549363/en/
Source: Electra Therapeutics, Inc.
View this news release online at:
http://www.businesswire.com/news/home/20240602549363/en
